Chapter 20.9
The Effect of Endocrine Diseases on Liver Function
Anthony J. DeSantis,
Andres T. Blei,
Anthony J. DeSantis
Search for more papers by this authorAndres T. Blei
Search for more papers by this authorAnthony J. DeSantis,
Andres T. Blei,
Anthony J. DeSantis
Search for more papers by this authorAndres T. Blei
Search for more papers by this authorBook Editor(s):Juan Rodés MD,
Jean-Pierre Benhamou MD,
Andres T. Blei MD,
Jürg Reichen MD,
Mario Rizzetto MD,
Juan Rodés MD
Director General, Hospital Clinic; Professor of Medicine, University of Barcelona, Barcelona, Spain
Search for more papers by this authorJean-Pierre Benhamou MD
Professor of Hepatology, Université Denis Diderot Paris 7, Assistance Publique — Hôpitaux de Paris and Inserm U773, Service d'Hépatologie, Hôpital Beaujon, Clichy, France
Search for more papers by this authorAndres T. Blei MD
Professor of Medicine and Surgery, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
Search for more papers by this authorJürg Reichen MD
Professor of Medicine, University of Bern; Chief of Hepatology, University Hospital, Bern, Switzerland
Search for more papers by this authorMario Rizzetto MD
Professor of Gastroenterology, University of Turin, Turin, Italy
Search for more papers by this authorFirst published: 18 June 2007
References
- Number of Americans with diabetes continues to increase (press release). Atlanta, GA: Center for Disease Control and Prevention; October 26 2005. Available at www.cdc.gov/ad/oc/media/pressrel/fs051026.htm.
- Wild S, Roglic G, Green A et al. (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27, 1047–1053.
- Foster KJ, Griffith AH, Dewbury K et al. (1980) Liver disease in patients with diabetes mellitus. Postgrad Med J 56, 767–772.
- Salmela PI, Sotaniemi EA, Niemi M et al. (1984) Liver function tests in diabetic patients. Diabetes Care 3, 248–254.
- Orrell JM, Neithercut WD, Henderson J et al. (1990) Raised liver associated enzyme activity and post-prandial bile acid concentrations in sera from treated diabetic outpatients. Diabetes Res Clin Pract 10, 51–57.
- Eriksson S, Eriksson KF, Bondesson L (1986) Nonalcoholic steato-hepatitis in obesity: a reversible condition. Acta Med Scand 220, 83–88.
- Najjar S, Ayash MA (1974) The Mauriac syndrome. Clin Pediatr 13, 723–725.
- Rosenbloom A, Giordano B (1977) Chronic overtreatment of insulin in children and adolescents. Am J Dis Child 131, 881–885.
- Marks J, Skyler J (1999) The liver and the endocrine system. In: ER Schiff MF Sorrell WC Maddrey (eds) Schiff's Diseases of the Liver, 8th edn. Philadelphia: Lippincott-Raven Publishers.
- Silverman J, Pories W, Caro J (1989) Liver pathology in diabetes mellitus and morbid obesity. Clinical, pathological, and biochemical considerations. Pathol Annu 24, 275–302.
- Silverman JF O'Brien KF Long S et al. (1990) Liver pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol 85, 1349–1355.
- Marchesini G, Brizi M, Morselli-Labate AM et al. (2000) Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 109, 171.
- Bugianesi E, McCullough AJ, Marchesini G (2005) Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 42, 987–1000.
- Caldwell S, Oelsner D, Iezzoni J et al. (1999) Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 29, 664–669.
- Angulo P (2002) Non-alcoholic fatty liver disease. N Engl J Med 346, 1221–1231.
- Angulo P, Keach J, Batts K et al. (1999) Independent predictors of liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 30, 1356–1362.
- Joseph A, Saverymuttu S, Al-Sam S et al. (1991) Comparison of liver histology with ultrasonography in assessing diffuse, parenchymal liver disease. Clin Radiol 43, 26–31.
- Saadeh S, Younossi ZM, Remer EM et al. (2002) The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123, 745–750.
- Longo R, Polleseelo P, Ricci C et al. (1995) Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. J Magn Reson Imaging 5, 281–285.
- Matteoni, C, Younossi Z Gramlich T et al. (1999) Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116, 1413–1419.
- Andersen T, Gluud C, Franzmann M et al. (1991) Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 12, 224–229.
- Luyckx FH, Desaive C, Thiry A et al. (1998) Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 22, 222–226.
- Palmer M, Schaffner F (1990) Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 99, 1408–1413.
- Rozental B, Biava C, Spencer H et al. (1967) Liver morphology and function tests in obesity and during total starvation. Am J Dig Dis 12, 198–208.
- Drenick E, Simmons F, Murphy J (1970) Effect on hepatic morphology of treatment of obesity by fasting, reducing diets, and small-bowel bypass. N Engl J Med 282, 829–834.
- Basaranoglu M, Acbay O, Sonsuz A (1999) A controlled trial of gemfibrizole in the treatment of patients with non-alcoholic steato-hepatitis (letter). J Hepatol 31, 384.
- Lavine J (2000) Vitamin E treatment of non-alcoholic steatohepatitis in children: a pilot study. J Pediatr 136, 734–738.
- Abdelmalek A, Angulo P, Jorgensen R et al. (2001) Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 96, 2711–2717.
- Laurin J, Lindor KD, Crippin JS et al. (1996) Ursodeoxycholic acid or clofibrate in the treatment of non alcohol-induced steatohepatitis: a pilot study. Hepatology 23, 1464–1467.
- Lindor KD, Kowdley KV, Heathcote EJ et al. (2004) Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 39, 770–778.
- Bajaj M, Suraamornkul S, Pratipanawatr T et al. (2003) Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 52, 1364–1370.
- Freedman R, Uwaifo G, Lutchman G et al. (2003) Changes in insulin sensitivity and improvements in liver histology in patients with nonalcoholic steatohepatitis (NASH) treated with pioglitazone (PIO) (abstract). Diabetes 52 (Suppl. 1), 76A.
- Acosta R, Molina E, O'Brien C et al. (2001) The use of pioglitazone in nonalcoholic steatohepatitis (abstract). Gastroenterology 120 (Suppl. 1), A546.
- Sanyal AJ, Mofrad PS, Contos MJ et al. (2004) A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2, 1107–1115.
- Neuschwander-Tetri B Brunt E Wehmeier K et al. (2003) Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis, and body weight in patients with non-alcoholic steatohepatitis. J Hepatol 38, 434–440.
- Horlander J, Kwo P, Cummings O (2001) Atorvastatin for the treatment of NASH (abstract). Gastroenterology 120 (Suppl.), A544.
- Kiyici M, Gulten M, Gurel S et al. (2003) Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol 17, 713–718.
- Nair S, Diehl A, Perille R (2002) Metformin in non-alcoholic steatohepatitis: efficacy and safety: a preliminary report (abstract). Gastroenterology 122 (4 Suppl.), Abstract 4.
- Marchesisni G, Brizi M, Bianchi G et al. (2001) Metformin in nonalcoholic steatohepatitis (letter). Lancet 358, 893–894.
- Khuri K, Shamma AM, Abourizk N (1985) Hepatitis B virus markers in diabetes mellitus. Diabetes Care 8, 250–253.
- Gray H, Wreghitt T Stratton I et al. (1995) High prevalence of hepatitis C infection in Afro-Caribbean patients with Type 2 diabetes and abnormal liver function tests. Diabet Med 12, 244–249.
- Simo R, Hernandez C, Genesca J et al. (1996) High prevalence of hepatitis C virus infection in diabetic patients. Diabetes Care 19, 998–1000.
- Lonardo A, Adinolfi L, Loria P et al. (2004) Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extra-hepatic disease. Gastroenterology 126, 586–597.
- Mason A, Lau J, Hoang N et al. (1999) Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 29, 328–333.
- Allison M, Wreghitt T, Palmer C et al. (1994) Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol 21, 1135–1139.
- de Marco R Locatelli F Zoppini G et al. (1999) Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 5, 756–761.
- Kingston M, Ali M, Atiyeh M et al. (1984) Diabetes mellitus in chronic active hepatitis and cirrhosis. Gastroenterology 87, 688–694.
- Lawson D, Gray J, McKillop C et al. (1986) Diabetes mellitus and primary hepatocellular carcinoma. Q J Med 61, 945–955.
- Adami H, Chow W, Nyren O et al. (1996) Excess of risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 88, 1472–1477.
- Wideroff L, Gridley G, Mellemkjaer L et al. (1997) Cancer incidence in a population based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 89, 1360–1365.
- Fujino Y, Mizoue T, Tokui N et al. (2001) Prospective study of diabetes mellitus and liver cancer in Japan. Diabetes Metab Res Rev 17, 374–379.
- El-Serag H Tran T Everhart J (2004) Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126, 460–468.
- Ito T, Sasaki Y, Wands J (1996) Overexpression of human insulin receptor substrate 1 induces cellular transformation with activation of mitogen-activated protein kinases. Mol Cell Biol 16, 943–951.
- Tanaka S, Wands J (1996) Insulin receptor 1 substrate over expression in human hepatocellular carcinoma cells prevents transforming growth factor beta 1-induced apoptosis. Cancer Res 56, 3391–3394.
- Lieber M (1952) The incidence of gallstones and their correlation with other diseases. Ann Surg 135, 394–405.
- DeSantis A, Attila A, Ginanni Corradini S et al. (1997) Gallstones and diabetes: a case-control study in a free living population sample. Hepatology 25, 787–790.
- Attili A, Capocaccia R, Carulli N et al. (1997) Factors associated with gallstone disease in the MICOL experience. Multicenter Italian Study of Epidemiology of Cholelithiasis. Hepatology 26, 809–818.
- Chapman B, Wilso I, Frampton C et al. (2000) Prevalence of gallbladder disease in diabetes mellitus. Dig Dis Sci 45, 2002–2006.
- Haffner S, Diehl A, Mitchell B et al. (1990) Increased prevalence of clinical gallbladder disease in subjects with non-insulin diabetes mellitus. Am J Epidemiol 132, 327–335.
- Haber G, Heaton K (1979) Lipid composition of bile in diabetics and obesity-matched controls. Gut 20, 518–522.
- Sturdevant RA, Pearce ML, Dayton S (1973) Increased prevalence of cholelithiasis in men ingesting a serum-cholesterol-lowering diet. N Engl J Med 288, 24–27.
- Stone B, Gavaler J, Belle S et al. (1988) Impairment of gallbladder emptying in diabetes mellitus. Gastroenterology 95, 170–176.
- Pazzi P, Scaliarini R, Gamberini S et al. (2000) Review article: gallbladder motor function in diabetes mellitus. Aliment Pharmacol Ther 14 (Suppl. 2), 62–65.
- Sandler R, Maule W, Baltus M (1986) Factors associated with postoperative complications in diabetics after biliary tract surgery. Gastroenterology 91, 157–162.
- Freidman L, Roberts M, Brett A et al. (1988) Management of asymptomatic gallstones in the diabetic patient. A decision analysis. Ann Intern Med 109, 913–919.
- Chan K, Truman A, Gurwitz J et al. (2003) A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents. Arch Intern Med 163, 728–734.
- Chojkier M (2005) Troglitazone and liver injury: in search of answers. Hepatology 41, 229–230.
- Zawadski J, Green L, Graham B (2002) Troglitazone-associated 15 month post-marketing hepatotoxicity. FDA Science Forum. Accessed at www.cfsan.fda.gov/˜frf/forum02/a187ab4.htm.
- Beckett G, Kellett H, Gow S et al. (1985) Raised plasma glutathione S-transferase values in hyperthyroidism and in hypothyroid patients receiving thyroxine replacement: evidence for hepatic damage. Br Med J 291 (6493), 427–431.
- Sola J Pardo-Mindan F Zozaya J et al. (1991) Liver changes in patients with hyperthyroidism. Liver 11, 193–199.
- Chung Y, Jung S, Song B et al. (2001) Plasma isocitrate dehydrogenase as a marker of centrilobular hepatic necrosis in patients with hyperthyroidism. J Clin Gastroenterol 33, 118–122.
- Fong T, McHutchison J, Reynolds T (1992) Hyperthyroidism and hepatic dysfunction. J Clin Gastroenterol 14, 240–224.
- Malik R, Hodgson H (2002) The relationship between the thyroid gland and the liver. Q J Med 95, 559–569.
- Klion FM, Segal R, Schaffner F (1971) The effect of altered thyroid function on the ultrastructure of the human liver. Am J Med 50, 317–324.
- Doran G (1978) Serum enzyme disturbances in thyrotoxicosis and myxedema. J R Soc Med 71, 189–194.
- Sandler MP, Robinson RP, Rabin D et al. (1983) The effect of thyroid hormones on gluconeogenesis and forearm metabolism in man. J Clin Endocrinol Metab 56, 479–485.
- Williams K, Nayak S, Becker D et al. (1997) Fifty years of experience with propylthiouracil-associated hepatotoxicity: what have we learned? J Clin Endocrinol Metab 82, 1727–1733.
- Seidman D, Livini E, Ilie B et al. (1986) Propylthiouracil-induced cholestatic jaundice. Clin Toxicol 24, 353–360.
- Ayensa C, Diazde Otazu R, Cia JM (1986) Carbimazole-induced cholestatic hepatitis. Arch Intern Med 146, 1455.
- Thobe N, Pilger P, Jones M (2000) Primary hypothyroidism masquerading as hepatic encephalopathy: case report and review of the literature. Postgrad Med J 76, 424–426.
- Van Steenbergen W Fevery J De Vos, R et al. (1989) Effects of hypothyroidism and hyperthyroidism on the hepatic transport of bilirubin mono- and diconjugates in the Wistar rat. Hepatology 2, 314–321.
- Labrune P, Myara A, Huguet P et al. (1992) Bilirubin uridine diphosphate glucuronosyltransferase hepatic activity in jaundice associated with congenital hypothyroidism. J Pediatr Gastroenterol Nutr 1, 79–82.
- Inkinen J, Sand J, Nordback I (2000) Association between common bile duct stones and treated hypothyroidism. Hepatogastroenterology 47, 919–921.
- Klein I, Levey G (1984) Unusual manifestations of hypothyroidism. Arch Intern Med 144, 123–128.
- Baker A, Kaplan M, Wolfe H (1972) Central congestive fibrosis of the liver in myxedema ascites. Ann Intern Med 77, 927–929.
- Huang M, Liaw Y (1995) Clinical associations between thyroid and liver diseases. J Gastroenterol Hepatol 10, 344–350.
- Olsson RG, Lindgren A, Zettergren L (1990) Liver involvement in Addison's disease. Am J Gastroenterol 85, 435–438.
- Boulton R, Hamilton MI, Dhillon AP et al. (1995) Subclinical Addison's disease: a cause of persistent abnormalities in transaminase values. Gastroenterology 109, 1324–1327.
- McIntyre N, Mulligan R, Carson E (1973) BSP Tm and S: a critical re-evaluation. In: G Paumgartner R Preisig (eds) The Liver: Quantitative Aspects of Structure and Function. Basel: Karger, pp. 417–427.
- Sato T, Tajiri J, Shimada T et al. (1984) Abnormal blood chemistry data in Cushing's syndrome: comparison with those for fatty liver. Endocrinol Jpn 31, 705–710.
- Jones JP Jr Engleman EP Najarian JS (1965) Systemic fat embolism after renal homotransplantation and treatment with corticosteroids. N Engl J Med 273, 1453–1458.
- Lake-Bakaar G Scheuer PJ Sherlock S (1987) Hepatic reactions associated with ketoconazole in the United Kingdom. Br Med J 294, 419–422.
- McCance DR, Hadden DR, Kennedy L et al. (1987) Clinical experience with ketoconazole as a therapy for patients with Cushing's syndrome. Clin Endocrinol 27, 593–599.
- Caitlin D (1995) Anabolic steroids. In: L DeGroot (ed.) Endocrinology. Philadelphia: Saunders, pp. 2362–2376.
- Ishak KG, Zimmerman HJ (1987) Hepatotoxic effects of the anabolic/androgenic steroids. Semin Liver Dis 7, 230–236.
- Bagheri SA, Boyer JL (1974) Peliosis hepatis associated with androgenic-anabolic steroid therapy. A severe form of hepatic injury. Ann Intern Med 81, 610–618.
- Cabasso A (1994) Peliosis hepatis in a young adult bodybuilder. Med Sci Sports Exerc 26, 2–4.
- Socas L, Zumbado M, Perez-Luzardo O et al. (2005) Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature. Br J Sports Med 39, e27.
- Hernandez-Nieto L Bruguera M Bombi J et al. (1977) Benign liver-cell adenoma associated with long-term administration of an androgenic-anabolic steroid (methandienone). Cancer 4 0 1761–1764.
- Nakao A, Sakagami K, Nakata Y et al. (2000) Multiple hepatic adenomas caused by long-term administration of androgenic steroids for aplastic anemia in association with familial adenomatous polyposis. J Gastroenterol 35, 557–562.
-
Grazioli L,
Federle MP,
Brancatelli G et al.
(2001)
Hepatic adenomas: imaging and pathologic findings.
Radiographics
4,
877–892.
10.1148/radiographics.21.4.g01jl04877 Google Scholar
- Monga M (2006) Hepatic adenomas: presumed innocent until proven to be beta-catenin mutated. Hepatology 43, 401–404.
- El-Serag HB (2004) Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127 (5 Suppl. 1 ), S27–34.
- Nagasue N, Yu L, Yukaya H et al. (1995) Androgen and oestrogen receptors in hepatocellular carcinoma and surrounding liver parenchyma: impact on intrahepatic recurrence after hepatic resection. Br J Surg 82, 542–547.
- Recant L, Lacy P (1965) Fanconi's anemia and hepatic cirrhosis. Am J Med 39, 464–475.
- Velazquez I, Alter BP (2004) Androgens and liver tumors: Fanconi's anemia and non-Fanconi's conditions. Am J Hematol 77, 257–267.
- Ain KB, Mori Y, Refetoff S (1987) Reduced clearance rate of thyroxine-binding globulin (TBG) with increased sialylation: a mechanism for estrogen-induced elevation of serum TBG concentration. J Clin Endocrinol Metab 65, 689–696.
- Grodstein F, Colditz GA, Hunter DJ et al. (1994) A prospective study of symptomatic gallstones in women: relation with oral contraceptives and other risk factors. Obstet Gynecol 84, 207–214.
- Hulley S, Furberg C, Barrett-Connor E et al.; ERS Research Group (2002) Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288, 58–66.
- Mamdani MM, Tu K, van Walraven, C et al. (2000) Postmenopausal estrogen replacement therapy and increased rates of cholecystectomy and appendectomy. Can Med Assoc J 162, 1421–1424.
- Nelson HD, Humphrey LL, Nygren P et al. (2002) Postmenopausal hormone replacement therapy: scientific review. JAMA 288, 872–881.
- Valla D, Le MG, Poynard T et al. (1986) Risk of hepatic vein thrombosis in relation to recent use of oral contraceptives. A case-control study. Gastroenterology 90, 807–811.
- Baum JK, Bookstein JJ, Holtz F et al. (1973) Possible association between benign hepatomas and oral contraceptives. Lancet 2, 926–929.
- Steinbrecher UP, Lisbona R, Huang SN et al. (1981) Complete regression of hepatocellular adenoma after withdrawal of oral contraceptives. Dig Dis Sci 26, 1045–1050.
- Buhler H, Pirovino M, Akobiantz A et al. (1982) Regression of liver cell adenoma. A follow-up study of three consecutive patients after discontinuation of oral contraceptive use. Gastroenterology 82, 775–782.
- Prentice RL (1991) Epidemiologic data on exogenous hormones and hepatocellular carcinoma and selected other cancers. Prev Med 20, 38–46.
- Yu MW, Chang HC, Chang SC et al. (2003) Role of reproductive factors in hepatocellular carcinoma: impact on hepatitis B- and C-related risk. Hepatology 38, 1393–1400.
- Sato N, Lindros KO, Baraona E et al. (2001) Sex difference in alcohol-related organ injury. Alcohol Clin Exp Res 25 (5 Suppl. ISBRA), 40S–45S.
- Shimizu I (2003) Impact of oestrogens on the progression of liver disease. Liver Int 23, 63–69.
- Ezzat S (1992) Hepatobiliary and gastrointestinal manifestations of acromegaly. Dig Dis 10, 173–180.
- Avagnina P, Martini M, Terzolo M et al. (1996) Assessment of functional liver mass and plasma flow in acromegaly before and after long-term treatment with octreotide. Metabolism 45, 109–113.
- Melmed S, Casanueva FF, Cavagnini, F et al.; Acromegaly Treatment Consensus Workshop Participants (2002) Guidelines for acromegaly management. J Clin Endocrinol Metab 87, 4054–4058.
- Shi YF, Zhu XF, Harris AG et al. (1993) Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients. J Clin Endocrinol Metab 76, 32–37.
- Ayuk J, Stewart SE, Stewart PM et al. (2002) Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. J Clin Endocrinol Metab 87, 4142–4146.
- Zhu XF, Harris AG, Yang MF et al. (1994) Effect of octreotide on dynamic excretion of bile in Chinese acromegalic patients assessed by [99mTc]EHIDA hepatobiliary scan. Dig Dis Sci 39, 284–288.
- van Liessum PA Hopman WP Pieters GF et al. (1989) Postprandial gallbladder motility during long term treatment with the long-acting somatostatin analog SMS 201–995 in acromegaly. J Clin Endocrinol Metab 69, 557–562.
- Trainer PJ, Drake WM, Katznelson L et al. (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegviso-mant. N Engl J Med 342, 1171–1177.
- Colao A, Pivonello R, Auriemma RS et al. (2006) Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 154, 467–477.
- Biering H, Saller B, Bauditz J et al.; German pegvisomant investigators (2006) Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. Eur J Endocrinol 154, 213–220.
- Salomon F, Cuneo RC, Hesp R et al. (1989) The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 321, 1797–1803
- Kaji H, Sakurai T, Iguchi G et al. (2002) Adult growth hormone deficiency in Japan: results of investigation by questionnaire. Endocr J 49, 597–604.
- Irie M, Itoh Y, Miyashita Y et al. (2004) Complications in adults with growth hormone deficiency — a survey study in Japan. Endocr J 51, 479–485.
